July 19, 2018 10:23 AM EDT
R&D

In two PhI­II wins for Al­ler­gan/Mol­e­c­u­lar Part­ners, wet AMD drug shows non-in­fe­ri­or­i­ty to Lu­cen­tis

Brittany Meiling

It’s good news for Al­ler­gan and Mol­e­c­u­lar Part­ners’ wet AMD drug. The duo an­nounced Thurs­day that abic­i­par has met its end­points in two Phase III …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times